Biomedical Engineering Reference
In-Depth Information
Distant metastasis-free survival
(DMFS)
Overall survival (OS)
Median
follow-
up
(years)
Good
prognostic
signature
Poor
prognostic
signature
Hazard
ratio
(HR)
Good
prognostic
signature
Poor
prognostic
signature
Hazard
ratio
(HR)
Period of
specimen
collection
First author
(year)
Patient
population
No. of
patients
Age of
patient
Histopathology
N.A.
N.A.
N.A.
(10y) 91
± 4%
(10y) 74
± 5%
N.A
Bender
(2009)
European
N.A
1637
N.A.
T1-T2, N0 or N+
7.1
n
= 772
n
= 865
(10y) 90%
(10y) 30%
HR 3.88;
95% CI
1.99-
7.58;
N.A.
N.A.
N.A
P
<
0.01
Knauer
(2009)
[Update
report of
Bender
(2009)]
European
1984-2009
541
N.A.
pT1-T3, N0-N1,
M0
7.1
n
= 252
n
= 289
N.A.
N.A.
N.A.
N.A
95%
82%
HR 3.88;
95% CI
1.99-
7.58;
(5y) BCSS
97%
(5y) BCSS
87%
HR 4.01;
95% CI
1.98-11.67;
P
P
<
= 0.05
0.01
Ishitobi
(2010)
Japanese
1998-2001
102
<70
N0
7.1
n
= 20
n
= 82
(
Continued
)
